Article
Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations.
Thoracic cancer - 1 Nov 2022
Kanbe Mio, Sunaga Noriaki, Hara Kenichiro, Sawada Hiiru, Wakamatsu Ikuo, Hara Kentaro, Muto Sohei, Sawada Yuri, Masubuchi Hiroaki, Sato Mari, Miura Yosuke, Tsurumaki Hiroaki, Yatomi Masakiyo, Sakurai Reiko, Koga Yasuhiko, Ohtaki Yoichi, Nagashima Toshiteru, Okano Naoko, Kubo Nobuteru, Maeno Toshitaka, Hisada Takeshi
Abstract excerpt
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are standard therapeutic agents for non-small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to be fully established. Here, we report a long-term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.